12-106318352-G-A
Variant summary
Our verdict is Likely benign. Variant got -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_152772.3(TCP11L2):c.302G>A(p.Gly101Asp) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000347 in 1,613,052 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 13/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Uncertain significance (★).
Frequency
Consequence
NM_152772.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Likely_benign. Variant got -2 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
TCP11L2 | NM_152772.3 | c.302G>A | p.Gly101Asp | missense_variant | 4/10 | ENST00000299045.8 | NP_689985.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
TCP11L2 | ENST00000299045.8 | c.302G>A | p.Gly101Asp | missense_variant | 4/10 | 1 | NM_152772.3 | ENSP00000299045 | P1 |
Frequencies
GnomAD3 genomes AF: 0.000171 AC: 26AN: 152104Hom.: 0 Cov.: 33
GnomAD3 exomes AF: 0.0000359 AC: 9AN: 251044Hom.: 0 AF XY: 0.0000368 AC XY: 5AN XY: 135704
GnomAD4 exome AF: 0.0000192 AC: 28AN: 1460830Hom.: 0 Cov.: 30 AF XY: 0.0000179 AC XY: 13AN XY: 726700
GnomAD4 genome AF: 0.000184 AC: 28AN: 152222Hom.: 0 Cov.: 33 AF XY: 0.000215 AC XY: 16AN XY: 74408
ClinVar
Submissions by phenotype
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 11, 2024 | The c.302G>A (p.G101D) alteration is located in exon 4 (coding exon 3) of the TCP11L2 gene. This alteration results from a G to A substitution at nucleotide position 302, causing the glycine (G) at amino acid position 101 to be replaced by an aspartic acid (D). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at